BR112018013121A2 - formulação de combinação farmacêutica - Google Patents

formulação de combinação farmacêutica

Info

Publication number
BR112018013121A2
BR112018013121A2 BR112018013121-0A BR112018013121A BR112018013121A2 BR 112018013121 A2 BR112018013121 A2 BR 112018013121A2 BR 112018013121 A BR112018013121 A BR 112018013121A BR 112018013121 A2 BR112018013121 A2 BR 112018013121A2
Authority
BR
Brazil
Prior art keywords
tablet
pharmaceutical combination
combination formulation
active ingredients
relates
Prior art date
Application number
BR112018013121-0A
Other languages
English (en)
Other versions
BR112018013121B1 (pt
Inventor
Ryu Jei-Man
Park Woo-Ile
Kang Kyoung-Hwan
Kim Woo-Kyung
Chae Ah-Reum
Kim Soo-Won
Jung Hyun-Woo
Lee Jae-Young
Original Assignee
Shin Poong Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58543052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112018013121(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shin Poong Pharmaceutical Co., Ltd. filed Critical Shin Poong Pharmaceutical Co., Ltd.
Publication of BR112018013121A2 publication Critical patent/BR112018013121A2/pt
Publication of BR112018013121B1 publication Critical patent/BR112018013121B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção se refere a um comprimido compreendendo candesartan ou candesartan cilexetil e anlodipino ou seu sal farmaceuticamente aceitável como ingredientes ativos, o comprimido usando um solubilizante particular a fim de melhorar, de forma significativa, a propriedades de estabilidade e dissolução dos ingredientes ativos. em adição, a presente invenção se refere a um método de preparação do comprimido.
BR112018013121-0A 2015-12-28 2016-12-28 Comprimido compreendendo candesartan ou candesartan cilexetil e anlodipino BR112018013121B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2015-0187679 2015-12-28
KR1020150187679A KR101710441B1 (ko) 2015-12-28 2015-12-28 안정성 및 용출성이 향상된 정제
PCT/KR2016/015439 WO2017116150A1 (ko) 2015-12-28 2016-12-28 약제학적 복합제제

Publications (2)

Publication Number Publication Date
BR112018013121A2 true BR112018013121A2 (pt) 2018-12-11
BR112018013121B1 BR112018013121B1 (pt) 2023-09-05

Family

ID=

Also Published As

Publication number Publication date
EP3398589A1 (en) 2018-11-07
ES2868602T3 (es) 2021-10-21
JP6797924B2 (ja) 2020-12-09
RU2018126354A3 (pt) 2020-05-12
JP2019500392A (ja) 2019-01-10
WO2017116150A1 (ko) 2017-07-06
US20190015339A1 (en) 2019-01-17
RU2736942C2 (ru) 2020-11-23
MY194591A (en) 2022-12-05
KR101710441B1 (ko) 2017-02-28
EP3398589A4 (en) 2019-08-28
PE20181374A1 (es) 2018-08-28
RU2018126354A (ru) 2020-01-31
CN108472257B (zh) 2020-12-04
CN108472257A (zh) 2018-08-31
EP3398589B1 (en) 2021-01-27
CO2018007821A2 (es) 2018-08-10
CA3009468A1 (en) 2017-07-06
PH12018501392A1 (en) 2019-02-27
MX2018007976A (es) 2019-03-28

Similar Documents

Publication Publication Date Title
NI201700011A (es) 2-(morfolin-4-il)-1,7-naftiridinas.
PH12015502002B1 (en) Tripeptide epoxy ketone protease inhibitors
ES2969363T3 (es) Formulaciones
BR112015009228A8 (pt) Formulação farmacêutica líquida estéril e forma de dosagem intraocular oftálmica líquida estéril para injeção
IN2013MU03583A (pt)
PH12015501982A1 (en) Pharmaceutical compositions comprising everolimus
BR112016007414A2 (pt) método de produção de um comprimido de monocamada, e, comprimido de monocamada
IN2013MU00711A (pt)
JO3326B1 (ar) مثبطات إيبوكسي كيتون بروتياز ثلاثي الببتيد
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
CL2014001959A1 (es) Compuestos derivados de fenil-1h-imidazo[1,2-b]pirazol sustituidos; procedimiento de preparacion; composicion farmaceutica; y el uso en el tratamiento del cancer.
UA118576C2 (uk) Фармацевтична композиція, яка містить бринзоламід
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
MX2016014699A (es) (s)-pirlindol o sus sales farmaceuticamente aceptables para uso en medicina.
CL2016000787A1 (es) Composición farmacéutica en forma de comprimido que comprende atazanavir y cobicistat; procedimiento de preparación; y uso de la composición para preparar un medicamento útil para tratar la infección por el virus de inmunodeficiencia humana (vih).
MX364652B (es) Formulacion farmaceutica que comprende ciclesonida.
BR112016015175A2 (pt) Formulação farmacêutica, método para a fabricação de uma formulação farmacêutica compreendendo sildenafila e clomipramina e comprimido
BR112017012608A2 (pt) composto, composição farmacêutica e uso de um composto
BR112018013121A2 (pt) formulação de combinação farmacêutica
BR112017014295A2 (pt) composição farmacêutica.
BR112017027082A2 (pt) composição farmacêutica, método para tratar infecção, extrato, método para reduzir a carga viral
PE20170201A1 (es) Formas de dosificacion farmaceutica
BR112016029761A8 (pt) composições compreendendo um derivado de ácido quinolona carboxílico e agentes efervescentes, uso das mesmas e forma cristalina do referido derivado
UA97982U (uk) Лікарський засіб седативної дії у вигляді таблеток
BR112017024356A2 (pt) clonidina e/ou derivados de clonidina para uso na prevenção de lesão na pele resultante de radioterapia

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/12/2016, OBSERVADAS AS CONDICOES LEGAIS